Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria

Area of Science:

• Cardiology
• Pharmacology

Background:

• The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) demonstrated a 6% relative risk reduction in cardiovascular events with simvastatin/ezetimibe versus simvastatin alone in acute coronary syndrome (ACS) patients.
• Strict inclusion criteria (LDL-C 50-125 mg/dL, no statins > simvastatin 40 mg) limit the generalizability of IMPROVE-IT findings to routine ACS care.

Purpose of the Study:

• To assess the proportion of acute coronary syndrome patients in a large healthcare system eligible for ezetimibe based on IMPROVE-IT criteria.
• To evaluate the potential for increased ezetimibe use if IMPROVE-IT criteria are not strictly adhered to.

Main Methods:

• Retrospective analysis of 219,625 acute coronary syndrome patients from the Veterans Affairs healthcare system over 5 years.
• Determined eligibility for ezetimibe based on strict IMPROVE-IT criteria.
• Assessed potential for expanded ezetimibe use in patients not meeting criteria due to potent statin use, statin intolerance, or elevated LDL-C.

Main Results:

• Only 31.6% (69,508/219,625) of ACS patients met the strict IMPROVE-IT eligibility criteria for ezetimibe.
• Among patients not meeting criteria, an additional 28% could potentially receive ezetimibe with statins more potent than simvastatin 40 mg.
• Further potential for ezetimibe use was identified in 7.1% with statin intolerance and 10.4% with LDL-C >125 mg/dL.

Conclusions:

• This study provides initial insights into the real-world implications of the IMPROVE-IT trial in a large healthcare system.
• While 31.6% of ACS patients meet strict criteria, a significant proportion could benefit from ezetimibe outside these parameters.
• Findings necessitate a discussion regarding ezetimibe's role in ACS patients on high-intensity statins or with statin intolerance.